Fanconi Anemia Clinical Trials 2026 — Find Recruiting Studies

About Fanconi Anemia

Fanconi anemia is a rare inherited bone marrow failure syndrome caused by biallelic mutations in any of 23 FANC genes encoding proteins involved in the FA-BRCA DNA damage repair pathway, which is essential for resolving DNA interstrand crosslinks and replication fork stress. The condition is characterized by progressive pancytopenia, congenital physical anomalies, and a markedly elevated risk of myelodysplastic syndrome, acute myeloid leukemia, and solid tumors particularly squamous cell carcinomas of the head and neck and gynecologic tract. The diagnosis is confirmed by chromosomal breakage analysis using diepoxybutane (DEB) or mitomycin C, which reveals characteristic hypersensitivity of FA cells.

Common Clinical Features

Progressive pancytopenia from bone marrow failure Radial ray anomalies (absent or hypoplastic thumbs, radial aplasia) Short stature and low birth weight Cafe-au-lait spots and skin hyperpigmentation Renal and urogenital structural anomalies Microcephaly and microphthalmia Elevated cancer risk including AML, MDS, and squamous cell carcinoma Endocrine abnormalities including growth hormone deficiency and hypothyroidism

Clinical Trial Eligibility Tips

What to know before applying to Fanconi Anemia trials.

Diagnosis must be confirmed by chromosomal breakage testing (DEB or MMC assay) and complementation group or gene mutation identified, as FA subtype significantly affects prognosis and trial eligibility.

Hematopoietic stem cell transplantation eligibility and conditioning regimen tolerability are critical considerations; FA patients require reduced-intensity conditioning due to DNA repair deficiency.

Cancer surveillance history and any prior malignancy diagnosis must be disclosed; many trials exclude patients with active or recent malignancy, while others are specifically designed for FA patients with MDS or AML.